About Asuragen
Asuragen is a Healthcare company based in Austin (United States) founded in 2006, and was acquired by Bio-Techne in March 2021. Assays and kits developer for molecular diagnostics. Asuragen has raised $80 million across 23 funding rounds from investors including Bio-Techne, HHS and PTV Healthcare Capital. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is ASURAGEN, INC. Its competitors include Guardant Health, Natera and Foundation Medicine; 3 of its 3 listed competitors have raised funding.
Company details
Asuragen was founded in 2006 in Austin, United States, as a provider of molecular diagnostics in genetics and oncology. Kits for genetic sequencing and cancer monitoring are offered, including AmplideX reagents for FMR1 gene analysis and Quantidex products for lung cancer and chronic myeloid leukemia quantification. FDA clearance has been obtained for several products, supporting research and clinical applications in the sector.
- Headquarters Austin, United States
- Stage Acquired
- SectorsHealthcare
- Website asuragen.com
- Social LinkedIn X Facebook YouTube
- Acquired by Bio-Techne (Mar 2021)
- Legal Name Asuragen, Inc.
- Total Equity Funding$80M (USD)
in 23 rounds
- Latest Funding Round$182.39K (USD), Grant
Sep 2019
- InvestorsBio-Techne
& 4 more
- Acquired byBio-Techne
(Mar 2021)
Apps and channels of Asuragen
its YouTube channel Asuragen has 19 subscribers.
Funding Insights of Asuragen
Asuragen has successfully raised a total of $80M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $182.39 thousand completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80M
- Total Rounds 23
- Last Round Grant — $182,393
- First Round $1.43M
(Jun 2006)
- Investors Count 4
Latest 10 of 23 funding rounds of Asuragen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $182,393 | Grant | – | – | |
| Sep 2019 | $227,126 | Grant | – | – | |
| Sep 2019 | $229,469 | Grant | – | – | |
| Jun 2019 | Grant | – | – | ||
| Sep 2018 | $224,999 | Grant | – | – | |
| Apr 2018 | $442,028 | Grant | – | – | |
| Apr 2017 | $224,984 | Grant | – | – | |
| Sep 2015 | $171,540 | Grant | – | – | |
| Jul 2014 | $225,000 | Grant | – | – | |
| Jul 2014 | $1.55M | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Asuragen
Asuragen has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Bio-Techne, HHS and PTV Healthcare Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science, medical device and healthcare companies | thpartners.net | San Francisco, United States | ||
| growthcapitalfund.us | ||||
Life Sciences focused VC firm investing in expansion & late stage start-ups in the US | 2003 | ptvhc.com | Austin, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of biotech reagents, instruments and clinical diagnostic products | 1981 | bio-techne.com | Minneapolis, United States |
Investor details for Asuragen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Asuragen
414 people are tracked at Asuragen (96 in leadership, 318 in team).
| Name | Role | Group |
|---|---|---|
Rachael Amato Assoc Cipd | HR Business Partner For EMEA | Leadership |
Ryan Dagon | Senior Director, Marketing Technology & Sales Enablement | Leadership |
Jen Souvignier | Global Director Of Commercial Training And Onboarding | Leadership |
Susan Plurad | Senior Manager, Field Applications - Immunoassay Business Unit Partner | Leadership |
James T. Hippel | EVP & CFO | Leadership |
Qi Cheng | VP, Quality & Regulatory | Leadership |
Marty Putnam | Vp, Immunoassay Technologies | Leadership |
Beth Sander | Director Of People | Leadership |
Lori Dawidowicz | Senior Director, Diagnostic Controls Business Unit | Leadership |
Johanne McGregor | Senior Director Of Marketing | Leadership |
Roberto Munoz | Director Of Quality | Leadership |
Michelle L. Collins | Senior Director, Corporate Development - Diagnostics & Genomics | Leadership |
Jim Hippel | Executive Vice President And Chief Financial Officer | Leadership |
Vincent Defrank | Director, Software Quality | Leadership |
Anonymous | VP, Global Human Resources | Leadership |
Erin Sheppard | Senior Manager, People Partner | Leadership |
Lindsey Rodger | Head Of Corporate Communications | Leadership |
Dawn Gast | Division Director, Bio-techne Diagnostics Division (bdd), Quality And Regulatory | Leadership |
Angela Chen | Vice President, Gm, APAC | Leadership |
Gaynor Worthington | HR Business Partner, EMEA | Leadership |
394 more people are available in the full profile.
Complete people profiles for Asuragen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Asuragen
4 dated milestones of Asuragen across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Asuragen is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Grant, of $182K.
- Exit Acquired by Bio-Techne.
Competitors of Asuragen
Asuragen has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Foundation Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. |
Detailed competitors of Asuragen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Asuragen
The website of Asuragen (asuragen.com) receives about 8.4K visits a month.
- Monthly visits8.4K
▲ 9.7% vs previous month
Websites whose visitors overlap most with Asuragen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ambion.com | 100% | View details | |||
| exiqon.com | 90% | View details | |||
| switchgeargenomics.com | 88% | View details | |||
| armagen.com | 82% | View details | |||
| santaris.com | 82% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Asuragen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Asuragen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Asuragen
Complete news archive for Asuragen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Asuragen
Asuragen was founded in 2006.
Asuragen is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Asuragen is a funded company, having raised a total of $80M across 23 funding rounds to date. The company's 1st funding round was a Grant of $1.55M, raised on Jun 2006.
Asuragen was founded in 2006 in Austin, United States, as a provider of molecular diagnostics in genetics and oncology. Kits for genetic sequencing and cancer monitoring are offered, including AmplideX reagents for FMR1 gene analysis and Quantidex products for lung cancer and chronic myeloid leukemia quantification. FDA clearance has been obtained for several products, supporting research and clinical applications in the sector.
Asuragen's top competitors include Guardant Health, Foundation Medicine and Natera.
Asuragen has 5 investors. Key investors include Bio-Techne, HHS, PTV Healthcare Capital, Telegraph Hill Partners, and Growth Capital Fund.
Asuragen operates through Asuragen, Inc..
Yes. Asuragen was acquired by Bio-Techne in March 2021.